AKAP9 deficiency and associated defects in T cell activation in tissues were associated with a reduction of disease in EAE as determined by neurological disease scoring (Fig. 4h) and histological evaluation (Fig. 4i). This evidence concerns the gene AKAP9 and nervous system disorder.